Journal: Cell

Article Title: Evolution of Cortical Neurogenesis in Amniotes Controlled by Robo Signaling Levels

doi: 10.1016/j.cell.2018.06.007

Figure Lengend Snippet: Functional Validation of Genetic Reagents and Test of Interaction between Robo and Notch Signaling, Related to , , and (A and B) Validation of dnRobo and myrRobo as dominant-negative and constitutively active for Robo signaling, respectively. In (A), growth cone collapse assay of growing axons from explants of embryonic mouse retinas, electroporated to express Gfp or dnRobo and exposed to recombinant Slit protein or vehicle solution. Failure of response to Slit upon dnRobo-overexpression demonstrates its dominant-negative effect (n = 44-58 growth cones per group, 3 independent experiments). In (B), branching assay of growing axons from single neurons of embryonic rat dorsal root ganglion, overexpressing Gfp alone or with myrRobo constructs as indicated. Exuberant axonal branching typically elicited by Slit-Robo signaling occurs in myrRobo-expressing neurons in the absence of Slit, demonstrating constitutive activation of Robo signaling (n = 5-10 neurons per group). (C–F) Validation of crispr constructs for disruption of Dll1 in mouse and human. (C) Top, sequence of the gRNA targeting mouse Dll1 , and schematic of the orientation and location of the targeting site (black arrow) within the mDll1 coding sequence (gray bar). Bottom, validation of Crispr-mediated editing of the mDll1 locus upon electroporation with gDll1 plus Cas9, but not with Cas9 alone. Different lanes correspond to independent electroporated embryos. M, molecular weight marker. Arrow indicates 1,025 bp amplicon, arrowheads indicate the products of PCR amplicon digestion by Syrveyor Nuclease (656 + 368 bp), absent in the Cas9-alone lanes. (D) Left, sequence of the gRNA targeting human Dll1 , and schematic of the orientation and location of the targeting site (black arrow) within the hDll1 coding sequence (gray bar). Right, chromograms for genome sequence validation of Crispr-mediated editing of the hDll1 locus upon electroporation of cerebral organoid with gDll1 plus Cas9. A 270bp fragment was inserted at position 54 of the coding sequence, introducing a STOP codon in position 76. (E and F) Effect of electroporating crDll1 in NCx (green cells) on the abundance of Dll1 protein (red). Details are examples VZ cells loosing Dll1 protein (arrowheads) from the cell surface upon crDll1 (n = 3 embryos per group). (G–K) Antibody stain for GFP and Robo1 or Dll1 in NCx at E13.5 upon electroporation of the indicated plasmid combinations at E12.5, and quantifications (paired t test). Arrowheads indicate area of increased Robo (n = 3 embryos per group). Values are mean + SEM; paired or independent samples t tests; ∗ p < 0.05; ns, not significant. Scale bars: 30 μm (E), 50 μm (G and H).

Article Snippet: After 24h of incubation, recombinant mouse Slit protein (R&D Systems) was added to the medium (250ng/μl) and the explants were fixed 1h later with PFA 2% during 15 min.

Techniques: Functional Assay, Biomarker Discovery, Dominant Negative Mutation, Recombinant, Over Expression, Construct, Expressing, Activation Assay, CRISPR, Disruption, Sequencing, Electroporation, Molecular Weight, Marker, Amplification, Staining, Plasmid Preparation

Journal: Bone Research

Article Title: PTH induced osteoblast Slit3 to decrease aberrant sensory innervation in degenerated vertebral endplates to relieve low back pain in mice

doi: 10.1038/s41413-025-00488-z

Figure Lengend Snippet: Osteoblasts respond to PTH treatment with increased Slit3 transcription and translation. mRNA expression of the Slit3 in the endplate tissue of WT young mice treated with Veh and aged mice treated with Veh or PTH for 1 month ( a ), and WT LSI mice treated with veh or PTH for 2 months ( b ) ( n = 3, one-way ANOVA with Tukey’s multiple comparisons test). c mRNA expression of the Slit3 in MC3T3 cells cultured in osteoblast-stimulated medium and subsequently treated with Veh or PTH at different doses for 3 days ( n = 3, t -test). d , e Protein expression level of Slit3 in MC3T3 cells cultured in osteoblast-stimulated medium and treated with Veh (PBS) or PTH for 3 days. ( n = 3, t -test). Representative images ( f ) and quantification ( g ) of IF staining of PGP9.5 positive primary DRG neuron fibers crossing the microgroove barrier (microfluid assay) cultured in condition medium (CM), CM + PTH, CM + PTH plus mouse Slit3 antibody (1 µg/mL), or CM + Veh (1X PBS) plus human recombinant Slit3 (1.25 µg/mL) for 1 week. Representative images showing co-immunostaining for OCN (green) and Slit3 (red) in the lumbar spine sections and quantitative analysis of number of Slit3 + cells in trabecular bone (TB) and endplate (EP) of aged mice ( h – j ) and PPR OCN −/− LSI mice ( k – m ) treated with PTH or Veh for 2 months. Scale bar: 100 µm. ( n ≥ 5, t -test). * P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.001

Article Snippet: A range of primary antibodies was used for this purpose, including those specific for mouse β3 tubulin (1:500, 2G10, Thermo Fisher), CGRP (1:1 000, sc-57053, Santa Cruz), PGP9.5 (1:1 000, SAB4503057, Sigma), IB4 (1:1 000, I21441 , Thermo Fisher), TH (1:1 000, AB152, Sigma), Slit3 (1:1 000, AF3629, Biotechne), E47 (1:1 000, sc-416, Santa Cruz), FoxA2 (1:1 000, 22474-1-AP, Proteintech), and GAPDH (1:2 000, 14C10, Cell Signaling), which facilitated the determination of protein concentrations in the lysates.

Techniques: Expressing, Cell Culture, Staining, Recombinant, Immunostaining

Journal: Bone Research

Article Title: PTH induced osteoblast Slit3 to decrease aberrant sensory innervation in degenerated vertebral endplates to relieve low back pain in mice

doi: 10.1038/s41413-025-00488-z

Figure Lengend Snippet: Transcriptional mechanism underpinning Slit3 secretion. a mRNA expression levels of Ets1, E47, FoxJ2 , and FoxA2 genes in MC3T3 cells cultured in osteoblast differentiation-inducing medium and treated with vehicle or PTH (100 nmol/L) for 3 days ( n = 3, t -test). b , c Protein expression level of E47, FoxA2 in MC3T3 cells cultured in stimulated medium and treated with PTH or Veh (PBS) for 3 days ( n = 3, t -test). Representative images depicting E47 IF staining (green) in lumbar vertebral body and endplate sections ( d ), quantitative analysis of the number of E47 + cells in the vertebral body ( e ) and endplate ( f ) of aged mice treated with Veh or PTH ( n = 5, t -tset). Scale bar: 100 µm. Representative images showing FoxA2 IF staining (red) in lumbar vertebral body and endplate sections ( g ), quantitative analysis of the number of FoxA2 + cells in the vertebral body ( h ) and endplate ( i ) of aged mice treated with PTH or vehicle for 2 months ( n = 5, t -tset). Scale bar: 100 µm. j Relative fold enrichment of the E47 binding site in the Slit3 promoter region from stimulated MC3T3 cells treated with vehicle or PTH (100 nmol/L) for 3 days ( n = 3, two-way ANOVA with Sidak’s multiple comparisons test). k Relative fold enrichment of the FoxA2 binding site in the Slit3 promoter region from stimulated MC3T3 cells treated with vehicle or PTH (100 nmol/L) for 3 days ( n = 3, two-way ANOVA with Sidak’s multiple comparisons test). * P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.001

Article Snippet: A range of primary antibodies was used for this purpose, including those specific for mouse β3 tubulin (1:500, 2G10, Thermo Fisher), CGRP (1:1 000, sc-57053, Santa Cruz), PGP9.5 (1:1 000, SAB4503057, Sigma), IB4 (1:1 000, I21441 , Thermo Fisher), TH (1:1 000, AB152, Sigma), Slit3 (1:1 000, AF3629, Biotechne), E47 (1:1 000, sc-416, Santa Cruz), FoxA2 (1:1 000, 22474-1-AP, Proteintech), and GAPDH (1:2 000, 14C10, Cell Signaling), which facilitated the determination of protein concentrations in the lysates.

Techniques: Expressing, Cell Culture, Staining, Binding Assay

Journal: Bone Research

Article Title: PTH induced osteoblast Slit3 to decrease aberrant sensory innervation in degenerated vertebral endplates to relieve low back pain in mice

doi: 10.1038/s41413-025-00488-z

Figure Lengend Snippet: Efficacy of PTH treatment is diminished in osteoblastic Slit3 knockout mice with spinal degeneration. Vertebral endplate bone structure analyses by micro-CT: bone volume per tissue volume (BV/TV) percentage ( a ), total porosity percentage ( b ), and total pore space ( c ) in Slit3 OCN −/− LSI mice with PTH (40 µg/kg/d) or Veh treatment for 2 months ( n = 7, t -test). Behavior evaluations included pressure tolerance of the lumbar spine assessed via the force threshold ( d ), total distance covered in spontaneous activity in 2 days ( e ), and latency of paw withdrawal post-thermal stimulation ( f ) for Slit3 OCN −/− LSI mice with PTH or Veh treatment for 2 months ( n = 7, t -test). g Western blot analysis of protein expression levels of β3 tubulin, CGRP, PGP9.5 relative to GAPDH in endplate tissue (L3-L5) in Slit3 OCN −/− LSI mice treated with PTH or Veh for 2 months. ( n = 5). Representative images of PGP9.5 (red) and CGRP (green)-positive fibers ( h ) and quantitative analysis of fiber length in the lumbar vertebral body of Slit3 OCN −/− LSI mice with PTH or Veh treatment ( i , j ) ( n = 5, t -tset). Scale bar: 100 µm. k Western blot analysis of protein expression levels of CGRP in DRG tissue (L1–L2), normalized to GAPDH expression, in Slit3 OCN −/− LSI mice treated with PTH or Veh for 2 months ( n = 5). Representative IF images showing CGRP-positive (green) neurons in DRG sections ( l ), followed by quantitative analysis of the mean IF intensity for CGRP ( m ) in the DRG of Slit3 OCN −/− LSI mice treated with PTH or Veh for 2 months ( n = 5, t -tset). Scale bar: 100 µm

Article Snippet: A range of primary antibodies was used for this purpose, including those specific for mouse β3 tubulin (1:500, 2G10, Thermo Fisher), CGRP (1:1 000, sc-57053, Santa Cruz), PGP9.5 (1:1 000, SAB4503057, Sigma), IB4 (1:1 000, I21441 , Thermo Fisher), TH (1:1 000, AB152, Sigma), Slit3 (1:1 000, AF3629, Biotechne), E47 (1:1 000, sc-416, Santa Cruz), FoxA2 (1:1 000, 22474-1-AP, Proteintech), and GAPDH (1:2 000, 14C10, Cell Signaling), which facilitated the determination of protein concentrations in the lysates.

Techniques: Knock-Out, Micro-CT, Activity Assay, Western Blot, Expressing

Journal: Current biology : CB

Article Title: FLRT3 is a Robo1-interacting protein that determines Netrin-1 attraction in developing axons.

doi: 10.1016/j.cub.2014.01.042

Figure Lengend Snippet: Figure 2. Slit1 Enables Netrin-1 Attraction by Activating the Robo1 Receptor

Article Snippet: Recombinant Slit1 (5 nM; R&D Systems), FLRT3-ECD [15] (1 mg/ml), a mouse anti-DCC antibody (AF5 clone; Abcam), or control mouse IgG was (J and K) Robo1+/+ rTCAs grow rostrally as a compact bundle (J), whereas the (L) Quantification of the data represented in (J) and (K). rTCA dispersion at the v tailed Student’s t test. (M) Scheme representing the topographic guidance of rTCAs and iTCAs in t Slit1 and Netrin-1 [21].

Techniques:

Journal: International immunopharmacology

Article Title: Human umbilical cord mesenchymal stem cells inhibit liver fibrosis via the microRNA-148a-5p/SLIT3 axis.

doi: 10.1016/j.intimp.2023.111134

Figure Lengend Snippet: Fig. 5. SLIT3 was a direct target of miR-148a-5p. (A) Venn diagram of the intersection of miR-148a-5p screened by miRDB and mirDIP databases. (B) Venn diagram of the intersection of potential genes regulated by hUC-MSCs and target genes of miR-148a-5p. (C) Luciferase activity assay on LX2 cells co-transfected with SLIT3 WT 3′ UTR-luciferase plasmid or SLIT3 MUT 3′ UTR-luciferase plasmid and miR-148a-5p mimics or miR-148a-5p NC. (D) The expression levels of SLIT3 in LX2 cells transfected with miR-148a-5p mimics. (E) The protein level of Col1α1 and α-SMA in LX2 cells co-treated with miR-148a-5p mimic and pcDNA-SLIT3.

Article Snippet: The membrane was subsequently blocked by immersion in a solution containing 5% skim milk in Tris-buffered saline containing Tween-20 for 1 h. The membranes were then exposed to primary antibodies and incubated overnight at a temperature of 4 ◦C: α-SMA (A17910, 1:1000, ABclonal), Col1a1 (ab138492, 1:1,000, Abcam), CD9 M. Yuan et al. International Immunopharmacology 125 (2023) 111134 (20597-1-AP, 1:2,000, Proteintech), CD81 (27855-1-AP, 1:2,000, Proteintech), TSG101 (A2216, 1:1,000, Abclonal), SLIT3 (DF9909, 1:1000, Affinity), and GAPDH (ab9485, 1:2,500, Abcam).

Techniques: Luciferase, Activity Assay, Transfection, Plasmid Preparation, Expressing

Journal: International immunopharmacology

Article Title: Human umbilical cord mesenchymal stem cells inhibit liver fibrosis via the microRNA-148a-5p/SLIT3 axis.

doi: 10.1016/j.intimp.2023.111134

Figure Lengend Snippet: Fig. 6. Downexpression of SLIT3 significantly inhibits the activation of LX2 cells. (A) The expression levels of SLIT3 in our RNA-seq data. (B-D) The expression levels of SLIT3 in mouse liver tissues and cell samples. (E-H) The expression level of SLIT3 in the exogenous dataset (GSE130129, GSE38648, GSE149508, and GSE68001, respectively). (I-J) Single-cell data for SLIT3 were explored in single-cell RNA-seq analyses of human liver tissues from GSE136103 (n = 5 healthy and n = 5 cirrhotic). (K) GO analysis of similar/interactive genes of SLIT3 in Metascape database. (L) GSEA analysis based on the high- and low-SLIT3 expression groups in liver fibrosis (GSE84044). (M) The expression level of Col1α1 and α-SMA after knockdown in LX2 cells by siRNAs (si-SLIT3 and si-NC) for 48 h.

Article Snippet: The membrane was subsequently blocked by immersion in a solution containing 5% skim milk in Tris-buffered saline containing Tween-20 for 1 h. The membranes were then exposed to primary antibodies and incubated overnight at a temperature of 4 ◦C: α-SMA (A17910, 1:1000, ABclonal), Col1a1 (ab138492, 1:1,000, Abcam), CD9 M. Yuan et al. International Immunopharmacology 125 (2023) 111134 (20597-1-AP, 1:2,000, Proteintech), CD81 (27855-1-AP, 1:2,000, Proteintech), TSG101 (A2216, 1:1,000, Abclonal), SLIT3 (DF9909, 1:1000, Affinity), and GAPDH (ab9485, 1:2,500, Abcam).

Techniques: Activation Assay, Expressing, RNA Sequencing, Knockdown

Journal: Scientific Reports

Article Title: Effects of neuroactive agents on axonal growth and pathfinding of retinal ganglion cells generated from human stem cells

doi: 10.1038/s41598-017-16727-1

Figure Lengend Snippet: Effect of SLIT1 supplementation on axonal growth of hESC- and hiPSC-derived RGCs. ( a ) Axonal growth of hESC- and hiPSC-derived RGCs is observed by immunostaining of NFL. In the control, hESC- and hiPSC-derived RGCs axons grow radially and straight (left panels). In contrast, the growth pattern of axons after SLIT1 supplementation is complex. Axonal growth of hESC- and hiPSC-derived RGCs is not inhibited by addition of 0.2 and 1.0 µg of SLIT1 supplementation from D27−30 (centre and right panels, respectively). However, axonal paths are disturbed (centre and right panels). The assessment at D27 is performed in RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. ( b ) Real-time PCR analysis of mRNA expression of axonal markers, TAU , NFL , and TUJ1 . Expression levels of axonal markers are not influenced by SLIT1 supplementation at any of the concentrations tested. Scale bar, 100 μm. Error bars indicate ± SD. Each column shows an average value for the studied samples. The sample size for all mRNA data is five (n = 5). NS, not significant.

Article Snippet: Recombinant human NGF, diluted in reduced Matrigel (BD Bioscience), was used at 10 ng/ml, and SEMA3A, diluted in reduced Matrigel (BD Bioscience), was used at a concentration of 200 ng/ml, while recombinant human SLIT1 (R&D Systems), diluted in Matrigel, was used at concentrations of 5 μg/ml at a temperature of approximately 4 °C.

Techniques: Derivative Assay, Immunostaining, Control, Real-time Polymerase Chain Reaction, Expressing

Journal: Scientific Reports

Article Title: Effects of neuroactive agents on axonal growth and pathfinding of retinal ganglion cells generated from human stem cells

doi: 10.1038/s41598-017-16727-1

Figure Lengend Snippet: Effect of locally sustained release of SLIT1 (5μg/ml) from hydrogels placed in front of the attached OVs. Locally sustained release of SLIT1 using hydrogel does not affect axonal growth of hESC- and hiPSC-derived RGCs (( a ) and ( d ), respectively, magnification 40x). Only a subset of axons is repelled by SLIT1 release (( b ) and ( e ), magnification 100x: squares in ( a ) and ( d ), respectively), while other axons remain unaffected. Filopodia of hESC- and hiPSC-derived RGCs (( c ) and ( f ), respectively) have collapsed in response to SLIT1 release, as evident from phalloidin and GAP43 staining. The assessment from D27 is performed under RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. Each experiment was repeated at least five times. Squares in ( a ) and ( d ) correspond to ( b ) and ( e ), respectively. Scale bars in ( a ) and ( d ), 100 μm. Scale bars in ( b ) and ( e ), 40 μm. Scale bars in ( c ) and ( f ), 10 μm.

Article Snippet: Recombinant human NGF, diluted in reduced Matrigel (BD Bioscience), was used at 10 ng/ml, and SEMA3A, diluted in reduced Matrigel (BD Bioscience), was used at a concentration of 200 ng/ml, while recombinant human SLIT1 (R&D Systems), diluted in Matrigel, was used at concentrations of 5 μg/ml at a temperature of approximately 4 °C.

Techniques: Derivative Assay, Staining

Journal: Scientific Reports

Article Title: Effects of neuroactive agents on axonal growth and pathfinding of retinal ganglion cells generated from human stem cells

doi: 10.1038/s41598-017-16727-1

Figure Lengend Snippet: The effect of focally sustained release of SLIT1 on pathfinding of axons derived from hESC- and hiPSC-derived RGCs. Phase-contrast images showing SLIT1-releasing beads (blue-coloured) placed next to the bottom of attached OV, and corresponding immunohistochemistry for the axons of the RGCs by NFL staining. ( a,c ) The paths of the axons of hESC- and hiPSCs- derived RGCs (( a ) and ( c ), respectively) stained by NFL radiate straight from the attached OV, even though the bead is located close by. ( b , d ) Compared with the control, the axons of hESC- and hiPSC-derived RGCs (( b ) and ( d ), respectively) are repelled by SLIT1 release from the bead, and axonal paths are not straight, but winding, and avoid the beads. The assessment from D27 is performed in RMM supplemented with 1.0% FBS and 100 ng/ml BDNF. Each experiment was repeated at least five times. Scale bars, 100 μm.

Article Snippet: Recombinant human NGF, diluted in reduced Matrigel (BD Bioscience), was used at 10 ng/ml, and SEMA3A, diluted in reduced Matrigel (BD Bioscience), was used at a concentration of 200 ng/ml, while recombinant human SLIT1 (R&D Systems), diluted in Matrigel, was used at concentrations of 5 μg/ml at a temperature of approximately 4 °C.

Techniques: Derivative Assay, Immunohistochemistry, Staining, Control

Journal: Scientific Reports

Article Title: Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors

doi: 10.1038/s41598-020-76555-8

Figure Lengend Snippet: ( A ) PCA of pituitary adenoma (PA) transcriptome showing three distinct clusters: POU1F1-driven GH-, TSH- and PRL-adenomas; NR5A1-driven gonadotropinomas and null cell adenomas; and TBX19-driven clinically evident ACTH adenomas. Silent ACTH PA grouped separately sharing features with both, TBX19-dependent and NR5A1-dependent adenomas. ( B ) Heatmap of the differentially expressed genes. In the “Y” axis tumor samples are grouped according to the World Health Organization (WHO) 2017 classification as gonadotrope cell adenomas, null-cell adenomas, clinically evident ACTH adenomas, clinically silent ACTH adenomas, somatotrope adenomas, prolactinomas and TSH adenomas; tumors are also classified in the figure according to clinical features such as size, invasion, recurrence and aggressiveness. The “X” axis represents the differentially expressed genes hierarchical cluster. ( C ) CACNA2D4 is upregulated in NR5A1-driven tumors; ( D ) EPHA4 is upregulated in TBX19-driven tumors; ( E ) SLIT1 is upregulated in POU1F1-driven tumors. Image was created using Partek Genomics Suite 7.19v ( https://www.partek.com/partek-genomics-suite/ ).

Article Snippet: For RT-qPCR of SLIT1 (Hs00171488_m1), EPHA4 (Hs00953178_m1) and CACNA2D4 (Hs00297782_m1) all reagents were purchased from Applied Biosystems (CA, USA), and conditions were as follows: 10 μl of Taqman Universal Master Mix II, 1 μl of each Taqman probe, 200 ng of cDNA in a 20 μl final volume, according to manufacturer’s recommendation.

Techniques:

Journal: Scientific Reports

Article Title: Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors

doi: 10.1038/s41598-020-76555-8

Figure Lengend Snippet: ( A – C ) Dot blots of representative up regulated genes. EPHA4 in TBX19-derived tumors , CACNA2D4 in NR5A1-derived tumors and SLIT1 in POU1F1-derived tumors. ( D – F ) Violin plots showing validation of gen up-regulation in each tumor group by RT-qPCR. Image was created using Partek Genomics Suite 7.19v ( https://www.partek.com/partek-genomics-suite/ ).

Article Snippet: For RT-qPCR of SLIT1 (Hs00171488_m1), EPHA4 (Hs00953178_m1) and CACNA2D4 (Hs00297782_m1) all reagents were purchased from Applied Biosystems (CA, USA), and conditions were as follows: 10 μl of Taqman Universal Master Mix II, 1 μl of each Taqman probe, 200 ng of cDNA in a 20 μl final volume, according to manufacturer’s recommendation.

Techniques: Derivative Assay, Biomarker Discovery, Quantitative RT-PCR